The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1365
May 30, 2011
View Complete Issue         Table of Contents 2019 
Issue 1365
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
In Brief: Fexofenadine (Allegra) and Fruit Juice
May 30, 2011 (Issue: 1365)
Fexofenadine (Allegra, and others) is the most recent second-generation H1-antihistamine to become available over the counter (OTC). Cetirizine (Zyrtec, and others) and loratadine (Claritin, and others) are already available OTC. Cetirizine can be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1365
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.